Pharmacokinetic Profile of Curcumin and Nanocurcumin in Plasma, Ovary, and Other Tissues

Abstract

Background Curcumin is a natural diphenolic compound that is currently being investigated for various cancers, including ovarian cancer. Clinical application of curcumin has been limited due to its low solubility and bioavailability and rapid metabolism and degradation at physiological pH. Particle size is one factor that can affect the absorption process, which thus increases compound solubility and transport across the membrane. This study was conducted to determine the effects of modifying the particle size of curcumin on its pharmacokinetic parameters in blood and other organs.

Methods Female Sprague Dawley rats were administered a single oral dose of 500 mg/kg curcumin or nanocurcumin. Blood samples were collected at 10, 15, 30, 45, 75, and 120 min, and ovaries, livers, kidneys, and colons were collected at 180 min. The levels of curcumin in plasma and organs were determined using UPLC-MS/MS, and the pharmacokinetic parameters were evaluated.

Results Curcumin levels were detectable and measurable in plasma and organs of rats that were administered curcumin or nanocurcumin. Overall, no statistically significant differences were found in pharmacokinetic parameters between curcumin and nanocurcumin groups in both plasma and organs, except for ovaries. The curcumin levels in plasma, liver, kidney, and colon in the curcumin group were higher than those in the nanocurcumin group. However, curcumin concentrations in ovaries in the nanocurcumin group were 3.6 times higher than those in the curcumin group.

Conclusion Particle size reduction of curcumin did not increase the concentration of curcumin in the plasma but increased its distribution in the ovaries.

Key words

curcumin - nanoparticle - pharmacokinetic - ovary

• References

• 1 Kurita T, Makino Y. Novel curcumin oral delivery systems. Anticancer Res 2013; 33: 2807-2822
• 2 Siviero A, Gallo E, Maggini V. et al. Curcumin, a golden spice with a low bioavailability. J Herb Med 2015; 5: 57-70
• 3 Aggarwal B, Harikumar K. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune, and neoplastic disease. Int J Biochem Cell Biol 2009; 41: 40-59
• 4 Kim BH, Lee ES, Choi R. et al. Protective effects of curcumin on renal oxidative stress and lipid metabolism in a rat model of type 2 diabetic nephropathy. Yonsei Med J 2016; 57: 664-673
• 5 Trujillo J, Chirino YI, Molina-Jijon E. et al. Renoprotective effect of the antioxidant curcumin: Recent findings. Redox Biol 2013; 1: 448-456
• 6 Palipoch S, Punsawad C, Koomhin P. et al. Hepatoprotective effect of curcumin and alpha-tocopherol against cisplatin-induced oxidative stress. BMC Complement. Altern Med 2014; 14: 1-8
• 7 Mun SH, Joung D, Kim Y. et al. Synergistic antibacterial effect of curcumin against methicillin-resistant Staphylococcus aureus. Phytomedicine 2013; 20: 714-718
• 8 Lin YG, Kunnumakkara AB, Nair A. et al. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-κB pathway. Clin Cancer Res 2007; 13: 3423-3430
• 9 Anand P, Kunnumakkara AB, Newman RA. et al. Bioavailability of curcumin: Problems and promises. Mol Pharm 2007; 4: 807-818
• 10 Wahlström B, Blennow G. A Study on the fate of curcumin in the rat. Acta Pharmacologica et Toxicologica 1978; 43: 86-92
• 11 Pan M, Huang T, Lin J. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos 1999; 2: 486-494
• 12 Yang KY, Lin LC, Tseng TY. et al. Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS. J Chromatogr B Anal Technol Biomed Life Sci 2007; 853: 183-189
• 13 Cheng AL, Hsu CH, Lin JK. et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk orpre-malignant lesions. Anticancer Res 2001; 21: 2895-2900
• 14 Sharma RA, Euden SA, Platton SL. et al. Phase I clinical trial of oral curcumin: Biomarkers of systemic activity and compliance. Clin Cancer Res 2004; 10: 6847-6854
• 15 Khadka P, Ro J, Kim H. et al. ScienceDirect pharmaceutical particle technologies: An approach to improve drug solubility, dissolution and bioavailability. Asian J Pharm Sci 2014; 9: 304-316
• 16 Li Z, Jiang H, Xu C. et al. Food hydrocolloids a review: Using nanoparticles to enhance absorption and bioavailability of phenolic phytochemicals. Food Hydrocoll 2014; 1-12
• 17 Song Z, Feng R, Sun M. et al. Curcumin-loaded PLGA-PEG-PLGA triblock copolymeric micelles: Preparation, pharmacokinetics and distribution in vivo. J Colloid Interface Sci 2011; 354: 116-123
• 18 Stewart BW, Wild CP. World cancer report 2014. World Heal Organ 2014; 1-2
• 19 Lev-Ari S, Strier L, Kazanov D. et al. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Clin Cancer Res 2005; 11: 6738-6744
• 20 Shi M, Cai Q, Yao L. et al. Antiproliferation and apoptosis induced by curcumin in human ovarian cancer cells. Cell Biol Int 2006; 30: 221-226
• 21 Kumar SS, Surianarayanan M, Vijayaraghavan M. et al. Curcumin loaded poly ( 2-hydroxyethyl methacrylate ) nanoparticles from gelled ionic liquid – In vitro cytotoxicity and anti-cancer activity. in. Eur J Pharm Sci 2014; 51: 34-44
• 22 Chen Y, Wu Y, He J. et al. The experimental and clinical study on the effect of curcumin on cell cycle proteins and regulating proteins of apoptosis in acute myelogenous leukemia. J Huazhong Univ Sci Technolog Med Sci 2002; 22: 295-298
• 23 Choudhuri T, Pal S, Agwarwal ML. et al. Curcumin induces apoptosis in human breast cancer cells through p53-dependent Bax induction. FEBS Lett 2002; 512: 334-340
• 24 Bhaumik S, Anjum R, Rangaraj N. et al. Curcumin mediated apoptosis in AK-5 tumor cells involves the production of reactive oxygen intermediates. FEBS Lett 1999; 456: 311-314
• 25 Radhakrishna Pillai G, Srivastava AS, Hassanein TI. et al. Induction of apoptosis in human lung cancer cells by curcumin. Cancer Lett 2004; 208: 163-170
• 26 Woo JH, Kim YH, Choi YJ. et al. Molecular mechanisms of curcumin-induced cytotoxicity: Induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl-XL and IAP, the release of cytochrome c and inhibition of Akt. Carcinogenesis 2003; 24: 1199-1208
• 27 Morin D, Barthélémy S, Zini R. et al. Curcumin induces the mitochondrial permeability transition pore mediated by membrane protein thiol oxidation. FEBS Lett 2001; 495: 131-136
• 28 Chen A, Xu J. Activation of PPARγ by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR. Am J Physiol Liver Physiol 2005; 288: G447-G456
• 29 European Medicine Agency. Guideline on bioanalytical method validation Guideline on bioanalytical method validation. 2012; 44: 1-23
• 30 Ravindranath VCN. Absorbtion and distribution of curcumin. Toxicology 1980; 16: 256-265
• 31 Duan JZ. Pharmacokinetics of oral absorption. In: Shargel L, Yu ABC. (Eds) Applied Biopharmaceutics and Pharmacokinetics. 7th Edition McGraw-Hill Eduation; New York: 2016. p. 177-204
• 32 Onoue S, Yamada S, Chan H. Nanodrugs: pharmacokinetics and safety. Int J Nanomedicine 2014; 9: 1025-1037
• 33 Jia L. Nanoparticle formulation increases oral bioavailability of poorly soluble drugs: Approaches experimental evidences and theory. Curr Nanosci 2005; 1: 237-243
• 34 Li C, Zhang Y, Su T. et al. Silica-coated flexible liposomes as a nanohybrid delivery system for enhanced oral bioavailability of curcumin. Int J Nanomedicine 2012; 7: 5995-6002
• 35 Khalil NM, do Nascimento CP, Casa DM. et al. Pharmacokinetics of curcumin-loaded PLGA and PLGA-PEG blend nanoparticles after oral administration in rats. Colloids Surfaces B Biointerfaces 2013; 101: 353-360
• 36 Lin Y, Tseng LC, Wang TY. et al. Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS. J Chromatogr B Anal Technol Biomed Life Sci 2007; 853: 183-189
• 37 Marczylo TH, Verschoyle RD, Cooke DN. et al. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother Pharmacol 2007; 60: 171-177
• 38 Maiti K, Mukherjee K, Gantait A. et al. Curcumin-phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats. Int J Pharm 2007; 330: 155-163
• 39 Putra IGNS, Nurcahaya BM, Rachmattika B. et al. Curcumin and its analogues as selective estrogen receptor modulators (SERMS): The study of docking method on estrogen alpha receptors. Pharmacon 2008; 9: 6-13
• 40 Liu W, Zhai Y, Heng X. et al. Oral bioavailability of curcumin: Problems and advancements. J Drug Target 2016; 24: 694-702
• 41 Schiborr C, Kocher A, Behnam D. et al. The oral bioavailability of curcumin from micronized powder and liquid micells is significantly increased in healthy humans and differs between sexes. Mol Nutr Food Res 2014; 58: 516-527